Main Article Content
Background: Type 2 diabetes mellitus (DM) is the most common cause of end- stage renal disease. Albuminuria is the foremost commonly utilized marker to anticipate onset of diabetic nephropathy (DN) without sufficient affectability and specificity to identify early DN.
Aim: This study aimed to evaluate plasma α-Klotho as a new biomarker for chronic diabetic nephropathy.
Methods: This cross sectional study included 125 Egyptian subjects attending the out Patients Clinic of the Department of Internal Medicine, 10Th of Ramadan city Health Insurance Hospital and divided into:-control group, patient with diabetic mellitus, patients with Diabetic nephropathy and patient with diabetic nephropathy and other complications. Patients were subjected to measurement of plasma α- Klotho, FBS, HbAIC, serum creatinine, serum urea, serum uric acid, k, Na, serum phosphorus, Albumin: Creatinine Ratio, GFR, Chol, TG, LDL HDL, AST, ALT, T.BIL, D.BIL ALB, TP, GLB and A/G ratio.
Results: Results showed that plasma a-klotho was significantly correlated with hemoglobin A1C, potassium, GFR, Albumin, TP and GLB. Meanwhile, plasma a- klotho was negatively correlated with duration of DM, CR, Urea, UR.A, Na, phosphorus, ACR, Chol, TG, LDL, AST, ALT, T.BIL, and D.BIL. However, there were no significant correlations between plasma α -klotho and FBS, HDL and A/G
ratio. At cut-off level ≥2.6, plasma α -klotho had 95% sensitivity and 81% specificity for diagnosing diabetic nephropathy.
Conclusion: α-klotho may be the chronic diabetic nephropathy markers for predicting renal injury in patients with type 2 diabetes.
Arora MK, Singh UK. Molecular mechanisms in the pathogenesis of diabetic nephropathy: An update. Vascul Pharmacol. 2013;58:259–271.
Halimi JM. The emerging concept of chronic kidney disease without clinical proteinuria in diabetic patients. Diabetes Metab. 2012;38:291–297.
Tramonti G, Kanwar YS. Review and discussion of tubular biomarkers in the diagnosis and management of diabetic nephropathy. Endocrine. 2013;43:494–503.
Kramer HJ, Nguyen QD, Curhan G, et al. Renal insufficiency in the absence of albuminuria and retinopathy among adults with type 2 diabetes mellitus. JAMA. 2003;289:3273–3277.
MacIsaac RJ, Tsalamandris C, Panagiotopoulos S, et al. Nonalbuminuric renal insufficiency in type 2 diabetes. Diabetes Care. 2004;27:195–200.
Kamijo-Ikemori A, Sugaya T, Kimura K. Novel urinary biomarkers in early diabetic kidney disease. Curr Diabetes Rep. 2014;14:513.
Macisaac RJ, Ekinci EI, Jerums G. Markers of and risk factors for the development and progression of diabetic kidney disease. Am J Kidney Dis. 2014;63(2 Suppl 2):S39–S62.
Titan SM, Zatz R, Graciolli FG, et al. FGF-23 as a predictor of renal outcome in diabetic nephropathy. Clin J Am Soc Nephrol. 2011;6:241–247.
Nielsen SE, Andersen S, Zdunek D, et al. Tubular markers do not predict the decline in glomerular filtration rate in type 1 diabetic patients with overt nephropathy. Kidney Int. 2011;79:1113–1118.
Tramonti G, Kanwar YS. Tubular biomarkers to assess progression of diabetic nephropathy. Kidney Int. 2011;79:1042–1044.
Wolkow PP, Niewczas MA, Perkins B, et al. Association of urinary inflammatory markers and renal decline in microalbuminuric type 1 diabetics. J Am Soc Nephrol. 2008;19:789–797.
Hinokio Y, Suzuki S, Hirai M, et al. Urinary excretion of 8- oxo-7, 8-dihydro-2′- deoxyguanosine as a predictor of the development of diabetic nephropathy. Diabetologia. 2002;45:877–882.
Krolewski AS, Warram JH, Forsblom C, et al. Serum concentration of cystatin C and risk of end-stage renal disease in diabetes. Diabetes Care. 2012;35:2311–2316.
Kuro-o M. Klotho in health and disease. Curr Opin Nephrol Hypertens. 2012;21:362–368.
Hu MC, Kuro-o M, Moe OW. Secreted klotho and chronic kidneydisease. Adv Exp Med Biol. 2012;728:126–157.
Kim HR, Nam BY, Kim DW, Kang MW, Han JH, et al. Circulating α-Klotho levels in CKD and relationship to progression. Am J Kidney Dis. 2013;61:899–909.
Lin Y, Kuro-O M, Sun Z. Genetic deficiency of anti- aging gene klothoexacerbates early nephropathy in STZ- induced diabetes in male mice.Endocrinology. 2013;154:3855–3863.
Hu MC, Moe OW. Klotho as a potential biomarker and therapy for acute kidney injury. Nat Rev Nephrol. 2012;8:423–429.
Kacso IM, Bondor CI, Kacso G. Soluble serum klotho in diabetic nephropathy: Relationship to VEGF-A. Clin Biochem. 2012;45:1415–1420.
Akimoto T, Yoshizawa H, Watanabe Y, Numata A, Yamazaki T, et al. Characteristics of urinary and serum soluble Klotho protein in patients with different degrees of chronic kidney disease. BMC Nephrol. 2012;13:155.
Devaraj S, Syed B, Chien A, Jialal I. Validation of an immunoassay for soluble Klotho protein: Decreased levels in diabetes and increased levels in chronic kidney disease. Am J Clin Pathol. 2012;137:479–485.
Asai O, Nakatani K, Tanaka T, Sakan H, Imura A, et al. Decreased renal α-Klotho expression in early diabetic nephropathy in humans and mice and its possible role in urinary calcium excretion. Kidney Int. 2012;81:539–547.
Zhao Y, Banerjee S, Dey N, LeJeune WS, Sarkar PS, et al. Klotho depletion contributes to increased inflammation in kidney of the db/db mouse model of diabetes via RelA (serine)536 phosphorylation. Diabetes. 2011;60:1907–1916.
Cha SK, Ortega B, Kurosu H, Rosenblatt KP, Kuro-O M, et al. Removal of sialic acid involving Klotho causes cell- surface retention of TRPV5 channel via binding to galectin-Proc Natl Acad Sci U S A. 2008;105:9805–9810.